Day: September 26, 2025

Accuray Launches All-in-One Radiotherapy Solution With Advanced Capabilities Designed to Set a New Standard in Cancer Care

September 26, 2025

MADISON, Wis., Sept. 26, 2025 /PRNewswire/ — Accuray Incorporated (NASDAQ: ARAY) announced today that the company is advancing its legacy of leadership in adaptive radiotherapy with the introduction of the Accuray Stellar™* Solution. Initially for the U.S. market, the new Accuray technology is not just a system, it’s a solution, comprised of a comprehensive tool set designed to empower clinical teams to address the evolving treatment needs of patients undergoing radiotherapy.

Nexalin Technology Announces Issuance of U.S. Patent Covering HALO Clarity Device Featuring DIFS Technology

September 26, 2025

The newly issued patent strengthens Nexalin’s expanding intellectual property estate, supporting the Company’s DIFS platform and ongoing clinical and regulatory initiatives

FluidAI Medical’s Origin™ device has received FDA 510(k) clearance, a pivotal milestone redefining the future of data-driven, post-operative care

September 26, 2025

In the news release, Fluid AI Medical Receives FDA 510(k) Clearance for Origin™, a Real-Time Postoperative Bedside Monitoring Device, issued 24-Sep-2025 by Fluid AI Medical over PR Newswire, we are advised by the company that the news release has been updated.

Thinking outside the box to fabricate customized 3D neural chips

September 26, 2025

Cultured neural tissues have been widely used as a simplified experimental model for brain research. However, existing devices for growing and recording neural tissues, which are manufactured using semiconductor processes, have limitations in terms of shape modification and the implementation of three-dimensional (3D) structures.

Time-released gel packs a one-two punch against aggressive brain tumors

September 26, 2025

High-grade gliomas are aggressive brain tumors with poor prognosis, largely because even after surgical removal, infiltrative residual tumor cells often regrow during the latency before radiotherapy, leading to recurrence.

Novel treatment is first to target underlying cause of rare kidney condition called C3G

September 26, 2025

Newcastle researchers have revealed the first treatment to target the underlying cause of a rare kidney condition called “C3G” and prevent the disease progressing.

Blog

- September 26, 2025

Accuray Launches All-in-One Radiotherapy Solution With Advanced Capabilities Designed to Set a New Standard in Cancer Care

Nexalin Technology Announces Issuance of U.S. Patent Covering HALO Clarity Device Featuring DIFS Technology

FluidAI Medical’s Origin™ device has received FDA 510(k) clearance, a pivotal milestone redefining the future of data-driven, post-operative care

Thinking outside the box to fabricate customized 3D neural chips

Time-released gel packs a one-two punch against aggressive brain tumors

Novel treatment is first to target underlying cause of rare kidney condition called C3G